Abstract

The colorectal cancer is the main causative factor for the morbidity and mortality in most of the developed countries. There are two risk factors mainly associated with the colon cancer, first is dietary conditions and the second one is genetic factors. After surgical treatment of colon cancer, the overall survival rate is fifty percentages (50%) and half of the surgery experience has recurrence to patients. The present study has provided a collective systematic review from the previous literatures and the data retrieved from different sources (PubMed, Sci-finder, and Scopus). Diverse research findings from the different organizations were retrieved, collected, compiled, and written in a systematic manner. This review comprehensively covers different approaches of drug delivery that are burgeoning in colorectal cancer treatment. These various approaches of drug delivery based on different anti-cancer drugs formulation (5- fluorouracil, cucumin, doxorubicin, paclitaxel and their combinations) have been proven to be a successful chemotherapeutic approach. Despite of the advancements in surgery as well as in adjuvant therapies, there is no tremendous reduction in colorectal cancer allied mortality. The overall observations and outcomes of this review conclude use of varied novel drug delivery systems viz. nanocarriers-based approaches, nanotheranostics, gene therapy, radiotherapy and other new-fangled drug delivery systems for the treatment of colorectal cancer owing to their effectiveness and safety. The present review suggests that burden of colon cancer is enormously large enough and it should be dealt with apt advanced and promising treatment strategies.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.